Skip to main content
NVDA+0.17%AAPL+1.92%GOOGL+1.84%MSFT+0.81%AMZN+2.02%TSM+1.15%SPCX+1.89%AVGO+0.30%META+0.57%TSLA+0.60%SKHY+0.94%MU-0.08%BRK-B+0.56%LLY-0.74%JPM+0.82%WMT+1.33%AMD+2.45%V+0.99%XOM+0.19%ASMLa+0.26%JNJ-0.15%INTC+2.55%MA+0.87%0700.HK+0.66%1398.HK0.00%ABBV+0.64%BAC+0.12%CSCO+4.21%ORCL-1.98%CVX+0.52%COST+0.35%KO+0.53%CAT+1.69%LRCX-0.11%DELL+11.62%AP2d+1.32%AMAT+0.42%HSBA.L+1.31%0005.HK-0.85%PG+1.39%UNH-2.36%MS+0.74%GE-0.14%3988.HK+1.34%1816.HK+0.46%NFLX+1.82%0857.HK-1.09%HD+1.04%GS+0.86%PM+0.93%NZDJPY-2.73%CHFJPY-2.46%AUDJPY-2.05%CADJPY-1.85%EURJPY-1.78%USDJPY-1.63%GBPJPY-1.55%GBPNZD+1.20%NZDUSD-1.14%EURNZD+0.99%GBPCHF+0.92%NZDCAD-0.90%USDCHF+0.86%AUDNZD+0.72%EURCHF+0.69%NOKJPY-0.63%CADCHF+0.61%PLNJPY-0.56%USDTHB+0.53%EURZAR-0.50%GBPAUD+0.48%CHFSGD-0.46%SGDJPY-0.45%AUDCHF+0.43%AUDUSD-0.42%GBPTRY+0.41%USDZAR-0.38%AUDNOK+0.37%AUDDKK+0.35%USDTRY+0.32%GBPHKD+0.32%NZDCHF-0.30%GBPCAD+0.29%GBPMXN-0.28%CHFNOK-0.28%EURAUD+0.27%NZDSGD+0.27%GBPZAR-0.26%USDCAD+0.23%CHFSEK-0.23%AUDCAD-0.22%EURCNH-0.22%EURGBP-0.22%USDSEK+0.19%AUDSGD+0.19%EURSGD-0.18%NZDMXN+0.17%USDILS+0.16%EURUSD-0.16%USDNOK+0.14%USDDKK+0.12%EURHKD-0.12%USDMXN-0.12%USDPLN+0.09%GBPUSD+0.08%GBPSGD+0.08%EURCAD+0.07%EURSEK+0.07%EURPLN-0.05%USDSGD-0.04%USDCOP-0.04%USDHKD+0.02%USDCNH+0.02%EURNOK+0.01%EURCZK-0.01%EURDKK-0.01%UKOIL-3.88%USOIL-3.37%GAGUSD+1.16%XAGUSD+1.16%XPTUSD+0.93%XAUUSD+0.66%GAUUSD+0.66%HG1+0.31%XNGUSD-0.09%SUGAR0.00%COCOA0.00%W10.00%BTCUSD+1.01%ETHUSD+4.20%USDTUSD+0.02%XRPUSD+1.99%SOLUSD+3.38%TRXUSDT-0.90%ZECUSDT+9.19%DOGEUSD+1.95%XMRUSDT+2.15%LINKUSD+1.11%XLMUSD+2.37%BCHUSDT+2.00%LTCUSD+2.65%UNIUSD+2.09%TONUSD+27.68%HBARUSDT-0.46%SUIUSD-0.05%TAOUSDT+0.48%AAVEUSD+3.13%DOTUSDT-4.63%ICPUSDT-1.88%ONDOUSDT+2.92%WLDUSDT+1.26%ARBUSDT+1.43%ATOMUSDT-7.78%JUPUSDT+7.70%INJUSDT-0.95%STXUSDT+0.08%FETUSDT+3.28%TIAUSDT-2.66%PYTHUSDT-0.12%SEIUSDT+0.56%IMXUSDT+1.66%WIFUSDT+0.21%GRTUSDT-0.02%OPUSDT+1.78%POLUSDT+4.26%IOTAUSDT-0.57%AXSUSDT+2.63%FARTCOINUSDT+2.99%EOSUSDT-1.21%DYDXUSDT+1.79%ORDIUSDT-0.02%GALAUSDT+0.30%NOTUSDT+3.12%RONINUSDT+1.10%NVDA+0.17%AAPL+1.92%GOOGL+1.84%MSFT+0.81%AMZN+2.02%TSM+1.15%SPCX+1.89%AVGO+0.30%META+0.57%TSLA+0.60%SKHY+0.94%MU-0.08%BRK-B+0.56%LLY-0.74%JPM+0.82%WMT+1.33%AMD+2.45%V+0.99%XOM+0.19%ASMLa+0.26%JNJ-0.15%INTC+2.55%MA+0.87%0700.HK+0.66%1398.HK0.00%ABBV+0.64%BAC+0.12%CSCO+4.21%ORCL-1.98%CVX+0.52%COST+0.35%KO+0.53%CAT+1.69%LRCX-0.11%DELL+11.62%AP2d+1.32%AMAT+0.42%HSBA.L+1.31%0005.HK-0.85%PG+1.39%UNH-2.36%MS+0.74%GE-0.14%3988.HK+1.34%1816.HK+0.46%NFLX+1.82%0857.HK-1.09%HD+1.04%GS+0.86%PM+0.93%NZDJPY-2.73%CHFJPY-2.46%AUDJPY-2.05%CADJPY-1.85%EURJPY-1.78%USDJPY-1.63%GBPJPY-1.55%GBPNZD+1.20%NZDUSD-1.14%EURNZD+0.99%GBPCHF+0.92%NZDCAD-0.90%USDCHF+0.86%AUDNZD+0.72%EURCHF+0.69%NOKJPY-0.63%CADCHF+0.61%PLNJPY-0.56%USDTHB+0.53%EURZAR-0.50%GBPAUD+0.48%CHFSGD-0.46%SGDJPY-0.45%AUDCHF+0.43%AUDUSD-0.42%GBPTRY+0.41%USDZAR-0.38%AUDNOK+0.37%AUDDKK+0.35%USDTRY+0.32%GBPHKD+0.32%NZDCHF-0.30%GBPCAD+0.29%GBPMXN-0.28%CHFNOK-0.28%EURAUD+0.27%NZDSGD+0.27%GBPZAR-0.26%USDCAD+0.23%CHFSEK-0.23%AUDCAD-0.22%EURCNH-0.22%EURGBP-0.22%USDSEK+0.19%AUDSGD+0.19%EURSGD-0.18%NZDMXN+0.17%USDILS+0.16%EURUSD-0.16%USDNOK+0.14%USDDKK+0.12%EURHKD-0.12%USDMXN-0.12%USDPLN+0.09%GBPUSD+0.08%GBPSGD+0.08%EURCAD+0.07%EURSEK+0.07%EURPLN-0.05%USDSGD-0.04%USDCOP-0.04%USDHKD+0.02%USDCNH+0.02%EURNOK+0.01%EURCZK-0.01%EURDKK-0.01%UKOIL-3.88%USOIL-3.37%GAGUSD+1.16%XAGUSD+1.16%XPTUSD+0.93%XAUUSD+0.66%GAUUSD+0.66%HG1+0.31%XNGUSD-0.09%SUGAR0.00%COCOA0.00%W10.00%BTCUSD+1.01%ETHUSD+4.20%USDTUSD+0.02%XRPUSD+1.99%SOLUSD+3.38%TRXUSDT-0.90%ZECUSDT+9.19%DOGEUSD+1.95%XMRUSDT+2.15%LINKUSD+1.11%XLMUSD+2.37%BCHUSDT+2.00%LTCUSD+2.65%UNIUSD+2.09%TONUSD+27.68%HBARUSDT-0.46%SUIUSD-0.05%TAOUSDT+0.48%AAVEUSD+3.13%DOTUSDT-4.63%ICPUSDT-1.88%ONDOUSDT+2.92%WLDUSDT+1.26%ARBUSDT+1.43%ATOMUSDT-7.78%JUPUSDT+7.70%INJUSDT-0.95%STXUSDT+0.08%FETUSDT+3.28%TIAUSDT-2.66%PYTHUSDT-0.12%SEIUSDT+0.56%IMXUSDT+1.66%WIFUSDT+0.21%GRTUSDT-0.02%OPUSDT+1.78%POLUSDT+4.26%IOTAUSDT-0.57%AXSUSDT+2.63%FARTCOINUSDT+2.99%EOSUSDT-1.21%DYDXUSDT+1.79%ORDIUSDT-0.02%GALAUSDT+0.30%NOTUSDT+3.12%RONINUSDT+1.10%
DT

Definium Therapeutics, Inc. (DFTX)

NASDAQ • Healthcare

$38.89
+$1.16 (+3.1%)
Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$37.65
Day Range$37.17 - $38.19
Avg. Volume (3M)1.6M
Market Cap$5B
52 Week Range
$8.77$49.7
Next EarningsIn 55 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$353.7M
EPS (TTM)
-$3.44
ROA (TTM)
-31.79%
Current Ratio
6.95

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-5.4%Q1 2026-$0.51
-51.1%Q2 2026-$0.71
-166.2%Q3 2026-$1.44
Next

Nov 5

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -166.2%

Definium Therapeutics’ adjusted EPS missed expectations as preliminary results for the second fiscal quarter of 2026, reported August 6, 2026, showed EPS of $-1.44 trailed the $-0.54 estimate, -166%. GAAP net loss widened to roughly $159.0 million, down -271.9% year over year from about $42.7 million, alongside operating income of about -$75.1 million as the company remained in a loss position for the quarter. On a per-share basis, EPS was down -188.0% year over year versus $-0.50 a year ago. Cash flow also reflected the loss-making profile, with negative operating cash flow of roughly $52.8 million. Consensus for the next period calls for EPS of $-0.54.

View full earnings history

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. is a NASDAQ-listed Healthcare company in Biotechnology that operates as a clinical-stage biopharmaceutical firm focused on brain health and neurological disorders. The company develops drug candidates for central nervous system conditions and, in qualitative terms, fits the profile of an early-stage biotech rather than a commercialized drug maker.

Name
Definium Therapeutics, Inc.
CEO
Robert Barrow
Website
definiumtx.com
Industry
Healthcare
Employees
106

Today's Snapshot

AI-generated

DFTX is trading 4% above yesterday's close, while its sector was flat. Definium Therapeutics won a second FDA Breakthrough Therapy designation for psilocybin to prevent chemotherapy nerve pain.

Trading Volume

Below 10d avg (1.5M)

803.5K

vs S&P 500 Today

Strong Outperformance

+3.00%

Updated: September 11, 2026 at 19:19 UTC

Technical Indicators

4 Buy1 Neutral3 Sell
DFTX trades around $39.30 and carries a modest buy bias. Short-term averages are supportive and price sits above the classic pivot, while the 200-day averages point to an extended uptrend; however, medium-term averages remain higher, tempering conviction. Momentum is mixed — a very low stochastic hints at short-term recovery even as MACD and RSI lean neutral to bearish — and ADX signals only moderate trend strength. Volatility is elevated and on-balance volume is subdued, suggesting limited acceleration behind the move. Technical takeaway: Modest buy bias.
All signals
  • EMA (5 indicators)$27.74 - $40.56
    Buy
  • RSI (14)41.67
    Neutral
  • Stochastic %K (14, 3, 3)11.34
    Buy
  • MACD Level (12, 26)-1.38
    Sell

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$23.78+1.8%
NRIXNurix Therapeutics, Inc.
$25.1-2.8%
URGNUroGen Pharma Ltd.
$42.31+0.2%
KODKodiak Sciences Inc.
$32.88+0.0%
XNCRXencor, Inc.
$24.42+0.7%
FTREFortrea Holdings Inc.
$17.19+1.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.